Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Controlled, Multicenter Phase 3 Study of AK112 in Combination with AK117 Versus Pembrolizumab As First Line Treatment for a Programmed Cell Death-ligand 1 (PD-L1) Positive Population with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Next Previous
X
Search
Trial Profile

A Randomized, Controlled, Multicenter Phase 3 Study of AK112 in Combination with AK117 Versus Pembrolizumab As First Line Treatment for a Programmed Cell Death-ligand 1 (PD-L1) Positive Population with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Status: Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Oct 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ivonescimab (Primary) ; Ligufalimab (Primary) ; Pembrolizumab
  • Indications Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Oropharyngeal cancer; Squamous cell cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Akeso Biopharma

    • Most Recent Events

    • 19 Sep 2024 Status changed from recruiting to not yet recruiting.
    • 17 Sep 2024 New trial record
    • 15 Sep 2024 According to an Akeso media release, company has initiated a phase 3 clinical study comparing ivonescimab combined with ligufalimab versus pembrolizumab for the first-line treatment of PD-L1 positive R/M HNSCC.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top